Pub Date : 2025-11-01DOI: 10.1016/j.rce.2025.502378
Á. García Tellado , B. Lucas-Velázquez , J. Pardo Lledías
{"title":"Captación en vasos de mediano calibre en PET/TC como indicio de arteritis de células gigantes extracraneal","authors":"Á. García Tellado , B. Lucas-Velázquez , J. Pardo Lledías","doi":"10.1016/j.rce.2025.502378","DOIUrl":"10.1016/j.rce.2025.502378","url":null,"abstract":"","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 9","pages":"Article 502378"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.rce.2025.502379
B. Ayuso García , Á. Marchán-López , H.J. Castro Pousada , E. Romay Lema , M.J. García-Pais , J. Corredoira Sánchez , P. Peinó Camba , Y. Chantres Legaspi , R. Monte Secades , R. Rabuñal Rey
Introduction
Perioperatively acquired COVID-19 may increase mortality. The aim of this study was to assess the influence of SARS-CoV-2 infection on the length of stay and mortality among surgical patients.
Methods
Retrospective study of surgical interventions performed between 1st March 2020 and 31st December 2022 after exclusion of minor procedures. Clinical, administrative, and epidemiological data were collected. Multivariate Cox regression analysis was conducted.
Results
19152 interventions were included. Patients had median age of 66 years (53-77), 53.8% were male, and the median number of conditions was 1 (0-3). Six hundred and twenty-two (3.2%) interventions were performed in COVID-19 patients, who were older (70 (57-80) vs. 67 (55-77) years; p = 0.003) and more comorbid (2 (1-3) vs. 1 (0-3); p < 0.001). COVID-19 patients had longer stays (11 (4-28) vs. 6 (3-12) days; p < 0.001), and higher mortality rates (incidence rate ratio 2.28 (1.70-3.00), p < 0.001). The adjusted hazard ratio was 1.54 (1.15-2.05), p = 0.001. Age, number of conditions, and incomplete vaccination, and surgeries conducted in 2022 (as compared to 2020 and 2021) were related to higher mortality. Mortality was higher during the first week of the infection, but not after that (HR 2.09 (1.04-4.21), p = 0.037), and the risk window narrowed after 2020.
Conclusions
Perioperative COVID-19 increases mortality, especially during the first week of the infection. Age, comorbidity, and vaccine status should also be considered when scheduling interventions.
{"title":"Impacto de la infección por SARS-CoV-2 sobre la mortalidad durante el periodo perioperatorio","authors":"B. Ayuso García , Á. Marchán-López , H.J. Castro Pousada , E. Romay Lema , M.J. García-Pais , J. Corredoira Sánchez , P. Peinó Camba , Y. Chantres Legaspi , R. Monte Secades , R. Rabuñal Rey","doi":"10.1016/j.rce.2025.502379","DOIUrl":"10.1016/j.rce.2025.502379","url":null,"abstract":"<div><h3>Introduction</h3><div>Perioperatively acquired COVID-19 may increase mortality. The aim of this study was to assess the influence of SARS-CoV-2 infection on the length of stay and mortality among surgical patients.</div></div><div><h3>Methods</h3><div>Retrospective study of surgical interventions performed between 1<sup>st</sup> March 2020 and 31<sup>st</sup> December 2022 after exclusion of minor procedures. Clinical, administrative, and epidemiological data were collected. Multivariate Cox regression analysis was conducted.</div></div><div><h3>Results</h3><div>19152 interventions were included. Patients had median age of 66 years (53-77), 53.8% were male, and the median number of conditions was 1 (0-3). Six hundred and twenty-two (3.2%) interventions were performed in COVID-19 patients, who were older (70 (57-80) vs. 67 (55-77) years; p<!--> <!-->=<!--> <!-->0.003) and more comorbid (2 (1-3) vs. 1 (0-3); p <<!--> <!-->0.001). COVID-19 patients had longer stays (11 (4-28) vs. 6 (3-12) days; p <<!--> <!-->0.001), and higher mortality rates (incidence rate ratio 2.28 (1.70-3.00), p <<!--> <!-->0.001). The adjusted hazard ratio was 1.54 (1.15-2.05), p<!--> <!-->=<!--> <!-->0.001. Age, number of conditions, and incomplete vaccination, and surgeries conducted in 2022 (as compared to 2020 and 2021) were related to higher mortality. Mortality was higher during the first week of the infection, but not after that (HR 2.09 (1.04-4.21), p<!--> <!-->=<!--> <!-->0.037), and the risk window narrowed after 2020.</div></div><div><h3>Conclusions</h3><div>Perioperative COVID-19 increases mortality, especially during the first week of the infection. Age, comorbidity, and vaccine status should also be considered when scheduling interventions.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 9","pages":"Article 502379"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.rce.2025.502381
R. Hurtado García, M. Lorente García, P. Cámara Cases
{"title":"Golpe a la arteria radial: el precio del tambor","authors":"R. Hurtado García, M. Lorente García, P. Cámara Cases","doi":"10.1016/j.rce.2025.502381","DOIUrl":"10.1016/j.rce.2025.502381","url":null,"abstract":"","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 9","pages":"Article 502381"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502356
M.A. Martínez Olmos , E. Venegas Moreno , M. Morales Conejo , L. Ceberio Hualde , B. Pérez , M. de Tallo Forga , F.J. Pérez-Sádaba , P. Correcher Medina
Objectives
To describe the sociodemographic and clinical characteristics and management of patients with phenylketonuria (PKU) followed in centres, services, and reference units (CSUR) or clinical excellence units specialised in inborn errors of metabolism (IEM). Additionally, to determine patients’ health-related quality of life (HRQoL).
Methods
Observational, cross-sectional, descriptive study conducted with Spanish PKU patients attending CSUR centres or clinical excellence units specialised in IEM during the study period.
Results
The study included 55 patients (54 adults and one teenager) with different PKU phenotypes. The mean (SD) age was 32.1 (9.7) years, with 69.1% women. The most frequent phenotype at diagnosis was classical PKU (67.3%). Mean (SD) plasma Phe levels at diagnosis were 901.9 (606.1) μmol/L and 422.8 (288.9) μmol/L in the last year. Neurological symptoms were present in 23.6% of patients, the most frequent being intellectual disability (21.8%). Psychological symptoms were present in 34.5% of patients, the most frequent being anxiety (14.5%) and depression (12.7%). Of the patients, 85.5% responded to the EQ-5D-5L questionnaire. Of these, 44.7% of patients reported no anxiety or depression, while 34.0% had mild anxiety or depression. The mean (SD) EQ-VAS value was 80.9 (15.2). Forty-one (74.5%) patients responded to the PKU-QoL questionnaire. The results indicated that PKU patients perceived the impact of their disease to be moderate across all domains included in the questionnaire.
Conclusions
Adults with PKU may experience neurological or psychological symptoms including intellectual disability, anxiety, and depression. However, their HRQoL was found to be good and comparable to that of the general population.
{"title":"Características clínicas y manejo de los pacientes españoles adultos con fenilcetonuria","authors":"M.A. Martínez Olmos , E. Venegas Moreno , M. Morales Conejo , L. Ceberio Hualde , B. Pérez , M. de Tallo Forga , F.J. Pérez-Sádaba , P. Correcher Medina","doi":"10.1016/j.rce.2025.502356","DOIUrl":"10.1016/j.rce.2025.502356","url":null,"abstract":"<div><h3>Objectives</h3><div>To describe the sociodemographic and clinical characteristics and management of patients with phenylketonuria (PKU) followed in centres, services, and reference units (CSUR) or clinical excellence units specialised in inborn errors of metabolism (IEM). Additionally, to determine patients’ health-related quality of life (HRQoL).</div></div><div><h3>Methods</h3><div>Observational, cross-sectional, descriptive study conducted with Spanish PKU patients attending CSUR centres or clinical excellence units specialised in IEM during the study period.</div></div><div><h3>Results</h3><div>The study included 55 patients (54 adults and one teenager) with different PKU phenotypes. The mean (SD) age was 32.1 (9.7) years, with 69.1% women. The most frequent phenotype at diagnosis was classical PKU (67.3%). Mean (SD) plasma Phe levels at diagnosis were 901.9 (606.1) μmol/L and 422.8 (288.9) μmol/L in the last year. Neurological symptoms were present in 23.6% of patients, the most frequent being intellectual disability (21.8%). Psychological symptoms were present in 34.5% of patients, the most frequent being anxiety (14.5%) and depression (12.7%). Of the patients, 85.5% responded to the EQ-5D-5L questionnaire. Of these, 44.7% of patients reported no anxiety or depression, while 34.0% had mild anxiety or depression. The mean (SD) EQ-VAS value was 80.9 (15.2). Forty-one (74.5%) patients responded to the PKU-QoL questionnaire. The results indicated that PKU patients perceived the impact of their disease to be moderate across all domains included in the questionnaire.</div></div><div><h3>Conclusions</h3><div>Adults with PKU may experience neurological or psychological symptoms including intellectual disability, anxiety, and depression. However, their HRQoL was found to be good and comparable to that of the general population.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502356"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502352
J. Carretero Gómez , J.M. Fernández Rodríguez , A. Michan Doña , J.P. Miramontes González , J.J. González Soler , M.I. Pérez Soto , F.J. Carrasco Sánchez , F. Gómez Delgado , J.C. Arévalo Lorido , P. Pérez Martínez , en representación del grupo de trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna (SEMI)
Obesity is currently recognized as a chronic, progressive, and relapsing disease, and constitutes a major global public health challenge. This document, promoted by the Spanish Society of Internal Medicine through its Working Group on Diabetes, Obesity, and Nutrition, outlines a comprehensive, multidisciplinary approach to care, with a specific focus on obesity-related comorbidities. Excess adipose tissue is conceptualized as a systemic pathogenic agent that actively contributes to the pathophysiology of numerous complications, including cardiovascular disease, heart failure, chronic kidney disease, osteoarthritis, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD). Furthermore, the document reviews the current evidence base regarding pharmacological interventions for obesity, addressing both their overall efficacy in weight management and their specific therapeutic impact in the context of the distinct obesity-associated comorbidities for which clinical benefit has been demonstrated.
The document endorses the implementation of the Edmonton Obesity Staging System (EOSS) as a pivotal framework for the clinical stratification of risk in individuals with obesity, facilitating a more nuanced and personalized therapeutic approach that prioritizes the functional, metabolic, and prognostic dimensions of the disease. In this context, the document proposes a paradigm shift in the therapeutic objectives for obesity management, moving beyond a sole reliance on anthropometric metrics, such as body mass index (BMI) or absolute weight reduction. Instead, it emphasizes a pathophysiological and patient-centered approach focused on the prevention of obesity-related complications, the early detection and management of its comorbid conditions, and the sustained improvement of both quality-adjusted and overall life expectancy, while simultaneously promoting the elimination of stigma and discrimination.
{"title":"Desde la obesidad a las comorbilidades: una propuesta de atención integral para ganar en salud de la Sociedad Española de Medicina Interna","authors":"J. Carretero Gómez , J.M. Fernández Rodríguez , A. Michan Doña , J.P. Miramontes González , J.J. González Soler , M.I. Pérez Soto , F.J. Carrasco Sánchez , F. Gómez Delgado , J.C. Arévalo Lorido , P. Pérez Martínez , en representación del grupo de trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna (SEMI)","doi":"10.1016/j.rce.2025.502352","DOIUrl":"10.1016/j.rce.2025.502352","url":null,"abstract":"<div><div>Obesity is currently recognized as a chronic, progressive, and relapsing disease, and constitutes a major global public health challenge. This document, promoted by the Spanish Society of Internal Medicine through its Working Group on Diabetes, Obesity, and Nutrition, outlines a comprehensive, multidisciplinary approach to care, with a specific focus on obesity-related comorbidities. Excess adipose tissue is conceptualized as a systemic pathogenic agent that actively contributes to the pathophysiology of numerous complications, including cardiovascular disease, heart failure, chronic kidney disease, osteoarthritis, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD). Furthermore, the document reviews the current evidence base regarding pharmacological interventions for obesity, addressing both their overall efficacy in weight management and their specific therapeutic impact in the context of the distinct obesity-associated comorbidities for which clinical benefit has been demonstrated.</div><div>The document endorses the implementation of the Edmonton Obesity Staging System (EOSS) as a pivotal framework for the clinical stratification of risk in individuals with obesity, facilitating a more nuanced and personalized therapeutic approach that prioritizes the functional, metabolic, and prognostic dimensions of the disease. In this context, the document proposes a paradigm shift in the therapeutic objectives for obesity management, moving beyond a sole reliance on anthropometric metrics, such as body mass index (BMI) or absolute weight reduction. Instead, it emphasizes a pathophysiological and patient-centered approach focused on the prevention of obesity-related complications, the early detection and management of its comorbid conditions, and the sustained improvement of both quality-adjusted and overall life expectancy, while simultaneously promoting the elimination of stigma and discrimination.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502352"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502354
M.A. Cornejo-Saucedo, J.M. Aparicio-Oliver, D. García-Gil
{"title":"Signo del macarrón y arteritis de Takayasu: utilidad de la ecografía clínica","authors":"M.A. Cornejo-Saucedo, J.M. Aparicio-Oliver, D. García-Gil","doi":"10.1016/j.rce.2025.502354","DOIUrl":"10.1016/j.rce.2025.502354","url":null,"abstract":"","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502354"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502350
A. García Tellado , A. Castillo Leonet , J. Queipo Menéndez , M. de la Fuente Vázquez , E. Julián Gómez , C. Valero , C. García Ibarbia , J. Pardo Lledias , J.L. Hernández Hernández
Introduction
Aortic arch calcification (AAC) is an underestimated marker of cardiovascular risk, associated with a higher incidence of major cardiovascular events and mortality.
Materials and methods
This retrospective, descriptive study included 292 patients admitted in May 2021 to the Internal Medicine Department of Marqués de Valdecilla University Hospital. The presence of AAC was assessed via chest X-rays, alongside clinical data, risk factors, and previous and 12-month cardiovascular events.
Results
AAC was present in 51% of patients. Age over 65, dyslipidemia, and smoking were independent predictors (P < .05). AAC was significantly associated with a higher prevalence of cardiovascular events: stroke (23.3% vs. 13.3%; OR: 1.9, 95% CI: 1.07-3.6), acute coronary syndrome (23.3% vs. 8.5%; OR: 3.2, 95% CI: 1.6-6.4), and peripheral arterial disease (20.9% vs. 7.3%; OR: 3.3, 95% CI: 1.6-6.9). At 12-month follow-up, patients with AAC had a higher incidence of new cardiovascular events (22.5% vs. 10.9%; OR: 2.3, 95% CI 1.2-4.9; P = .007). Although overall survival was lower in this group, only age and chronic kidney disease were independent predictors of mortality.
Conclusions
AAC is a common finding among hospitalized patients and is associated with increased cardiovascular risk. Its detection on chest X-rays may serve as an accessible tool for risk stratification in high-risk populations.
主动脉弓钙化（aortic arch calcification， AAC）是一个被低估的心血管风险指标，与较高的主要心血管事件发生率和死亡率相关。材料和方法本回顾性描述性研究纳入了2021年5月在马奎斯瓦德西拉大学医院内科收治的292例患者。通过胸部x光片、临床数据、危险因素、既往和12个月心血管事件评估AAC的存在。结果51%的患者存在saac。65岁以上、血脂异常和吸烟是独立预测因素（P < 0.05）。AAC与较高的心血管事件发生率显著相关：卒中（23.3%比13.3%;OR: 1.9, 95% CI: 1.07-3.6）、急性冠状动脉综合征（23.3%比8.5%;OR: 3.2, 95% CI: 1.6-6.4）和外周动脉疾病（20.9%比7.3%;OR: 3.3, 95% CI: 1.6-6.9）。在12个月的随访中，AAC患者的新发心血管事件发生率更高（22.5% vs 10.9%; OR: 2.3, 95% CI 1.2-4.9; P = 0.007）。尽管该组的总生存率较低，但只有年龄和慢性肾脏疾病是死亡率的独立预测因子。结论saac在住院患者中是一种常见的发现，并与心血管风险增加有关。胸部x光检查可作为高危人群风险分层的便捷工具。
{"title":"Significado de la calcificación del arco aórtico como marcador de riesgo cardiovascular: análisis de una cohorte de pacientes hospitalizados en Medicina Interna","authors":"A. García Tellado , A. Castillo Leonet , J. Queipo Menéndez , M. de la Fuente Vázquez , E. Julián Gómez , C. Valero , C. García Ibarbia , J. Pardo Lledias , J.L. Hernández Hernández","doi":"10.1016/j.rce.2025.502350","DOIUrl":"10.1016/j.rce.2025.502350","url":null,"abstract":"<div><h3>Introduction</h3><div>Aortic arch calcification (AAC) is an underestimated marker of cardiovascular risk, associated with a higher incidence of major cardiovascular events and mortality.</div></div><div><h3>Materials and methods</h3><div>This retrospective, descriptive study included 292 patients admitted in May 2021 to the Internal Medicine Department of Marqués de Valdecilla University Hospital. The presence of AAC was assessed via chest X-rays, alongside clinical data, risk factors, and previous and 12-month cardiovascular events.</div></div><div><h3>Results</h3><div>AAC was present in 51% of patients. Age over 65, dyslipidemia, and smoking were independent predictors (<em>P</em> <!--><<!--> <!-->.05). AAC was significantly associated with a higher prevalence of cardiovascular events: stroke (23.3% vs. 13.3%; OR: 1.9, 95%<!--> <!-->CI: 1.07-3.6), acute coronary syndrome (23.3% vs. 8.5%; OR: 3.2, 95%<!--> <!-->CI: 1.6-6.4), and peripheral arterial disease (20.9% vs. 7.3%; OR: 3.3, 95%<!--> <!-->CI: 1.6-6.9). At 12-month follow-up, patients with AAC had a higher incidence of new cardiovascular events (22.5% vs. 10.9%; OR: 2.3, 95%<!--> <!-->CI 1.2-4.9; <em>P</em> <!-->=<!--> <!-->.007). Although overall survival was lower in this group, only age and chronic kidney disease were independent predictors of mortality.</div></div><div><h3>Conclusions</h3><div>AAC is a common finding among hospitalized patients and is associated with increased cardiovascular risk. Its detection on chest X-rays may serve as an accessible tool for risk stratification in high-risk populations.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502350"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502353
Laura Aragonès Rodríguez , Elvira Bisbe Vives
{"title":"Atención Integral a Médicas Víctimas de Violencia Machista: el modelo del Colegio de Médicos de Barcelona","authors":"Laura Aragonès Rodríguez , Elvira Bisbe Vives","doi":"10.1016/j.rce.2025.502353","DOIUrl":"10.1016/j.rce.2025.502353","url":null,"abstract":"","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502353"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rce.2025.502344
J.M. Mostaza , C. Lahoz , M. García de Yébenes Castro , J.M. Rubio Campal , E. Velásquez , A. Ibarra Gutiérrez , J.F. Díaz , N. Plana , M. Rodríguez-Mañero , J.D. de Dios García-Díaz , F. Martínez Debén , I. Pavón de Paz , A.L. Catapano , G. Díaz Moya , K.K. Ray , en representación del grupo de investigadores de SANTORINI España
Introduction
Real-world studies evaluating the impact of 2019 European Societies of Cardiology (ESC) and Atherosclerosis (EAS) guidelines on the use of lipid-lowering treatments (LLTs) are scarce. This manuscript shows baseline and 1-year follow-up data on LLT usage and low-density lipoprotein cholesterol (LDL-C) goal attainment in the Spanish subpopulation from SANTORINI study and put them in perspective with the European cohort without Spanish participants.
Methods
SANTORINI was a multinational, prospective, non-interventional study. The Spanish subpopulation involved up to 1018 patients at high and very high cardiovascular (CV) risk.
Results
Of 956 patients in LDL-C dataset, mean LDL-C levels decreased from baseline (82.7 ± 40.6 mg/dL) to 1-year follow-up (72.3 ± 32.6 mg/dL), in patients at high and very high risk. The percentage of patients who achieved 2019 ESC/EAS LDL-C goals increased from 26.5% at baseline to 34.1% at 1-year follow-up, in patients at high (23.1% versus 27.3%) and very high risk (27.9% versus 37.0%). Attainment to LDL-C targets improved while initiating treatment with a LLT in patients not receiving it at baseline or following change to a combination therapy in those who were receiving it. During the follow-up, seven patients died due to CV causes, and 46 and 24 had at least one four- or three-component major adverse CV events, respectively.
Conclusions
Follow-up data from SANTORINI Spain show that LLT usage increased from baseline, including monotherapy and combination therapy. Despite recommendations, patients at highest CV risk continue not receiving the most adequate LLT for reducing LDL-C levels in routine clinical practice.
{"title":"Uso de fármacos hipolipemiantes en pacientes con alto y muy alto riesgo cardiovascular en España: un año de seguimiento de la subpoblación española del estudio europeo SANTORINI","authors":"J.M. Mostaza , C. Lahoz , M. García de Yébenes Castro , J.M. Rubio Campal , E. Velásquez , A. Ibarra Gutiérrez , J.F. Díaz , N. Plana , M. Rodríguez-Mañero , J.D. de Dios García-Díaz , F. Martínez Debén , I. Pavón de Paz , A.L. Catapano , G. Díaz Moya , K.K. Ray , en representación del grupo de investigadores de SANTORINI España","doi":"10.1016/j.rce.2025.502344","DOIUrl":"10.1016/j.rce.2025.502344","url":null,"abstract":"<div><h3>Introduction</h3><div>Real-world studies evaluating the impact of 2019 European Societies of Cardiology (ESC) and Atherosclerosis (EAS) guidelines on the use of lipid-lowering treatments (LLTs) are scarce. This manuscript shows baseline and 1-year follow-up data on LLT usage and low-density lipoprotein cholesterol (LDL-C) goal attainment in the Spanish subpopulation from SANTORINI study and put them in perspective with the European cohort without Spanish participants.</div></div><div><h3>Methods</h3><div>SANTORINI was a multinational, prospective, non-interventional study. The Spanish subpopulation involved up to 1018 patients at high and very high cardiovascular (CV) risk.</div></div><div><h3>Results</h3><div>Of 956 patients in LDL-C dataset, mean LDL-C levels decreased from baseline (82.7<!--> <!-->±<!--> <!-->40.6<!--> <!-->mg/dL) to 1-year follow-up (72.3<!--> <!-->±<!--> <!-->32.6<!--> <!-->mg/dL), in patients at high and very high risk. The percentage of patients who achieved 2019 ESC/EAS LDL-C goals increased from 26.5% at baseline to 34.1% at 1-year follow-up, in patients at high (23.1% versus 27.3%) and very high risk (27.9% versus 37.0%). Attainment to LDL-C targets improved while initiating treatment with a LLT in patients not receiving it at baseline or following change to a combination therapy in those who were receiving it. During the follow-up, seven patients died due to CV causes, and 46 and 24 had at least one four- or three-component major adverse CV events, respectively.</div></div><div><h3>Conclusions</h3><div>Follow-up data from SANTORINI Spain show that LLT usage increased from baseline, including monotherapy and combination therapy. Despite recommendations, patients at highest CV risk continue not receiving the most adequate LLT for reducing LDL-C levels in routine clinical practice.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502344"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号